The FDA has approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin as a neoadjuvant therapy, followed by adjuvant durvalumab after radical cystectomy for adults with muscle-invasive bladder cancer (MIBC). This marks the first ...